Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick2_001007

    Menu

    Prestwick2_001007

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Takeda Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion

              Details:

              The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.

              Lead Product(s): Fursultiamine

              Therapeutic Area: Ophthalmology Product Name: Alinamin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Blackstone Life Sciences

              Deal Size: $2,300.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment August 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY